New study observes best ways to treat hemophilia a when standard meds fail
NCT ID NCT04023019
First seen Nov 01, 2025 · Last updated May 09, 2026 · Updated 22 times
Summary
This study watches how doctors treat men with hemophilia A whose bodies have developed antibodies (inhibitors) that block standard clotting factor. Researchers will track different treatment plans, including immune tolerance therapy and newer drugs like emicizumab, to see which works best. About 120 participants will be followed for up to 5 years to measure bleeding rates and treatment success.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Arthur M. Blank Hospital
RECRUITINGAtlanta, Georgia, 30329, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
HZRM Hämophilie-Zentrum Rhein Main
RECRUITINGMörfelden-Walldorf, 64546, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.